The table below shows 10x Genomics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$136.05M
$6.66M
-$15.20M
-$33.61M
-$21.37M
-$217.90M
Capital expenditure
$5.93M
$12.39M
$48.60M
$131.66M
$101.28M
$36.67M
Investing cash flow
-$13.44M
-$32.63M
$133.49M
-$350.89M
-$106.73M
-$38.39M
Dividends paid
-
-
-
-
-
TXG operating cash flow (10-K history)
10x Genomics, Inc. reported operating cash flow of $136.05M for fiscal year 2025. That is up 1941.6% from $6.66M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$10.70M (FY 2017) to $136.05M. Figures come from the company's audited annual reports as filed with the SEC.
